Literature DB >> 27759773

PROGNOSTIC FACTORS AND SURVIVAL ANALYSIS IN ESOPHAGEAL CARCINOMA.

Francisco Tustumi1, Cintia Mayumi Sakurai Kimura1, Flavio Roberto Takeda1, Rodrigo Hideki Uema1, Rubens Antônio Aissar Salum1, Ulysses Ribeiro-Junior1, Ivan Cecconello1.   

Abstract

Background: Despite recent advances in diagnosis and treatment, esophageal cancer still has high mortality. Prognostic factors associated with patient and with disease itself are multiple and poorly explored. Aim: Assess prognostic variables in esophageal cancer patients.
Methods: Retrospective review of all patients with esophageal cancer in an oncology referral center. They were divided according to histological diagnosis (444 squamous cell carcinoma patients and 105 adenocarcinoma), and their demographic, pathological and clinical characteristics were analyzed and compared to clinical stage and overall survival.
Results: No difference was noted between squamous cell carcinoma and esophageal adenocarcinoma overall survival curves. Squamous cell carcinoma presented 22.8% survival after five years against 20.2% for adenocarcinoma. When considering only patients treated with curative intent resection, after five years squamous cell carcinoma survival rate was 56.6 and adenocarcinoma, 58%. In patients with squamous cell carcinoma, poor differentiation histology and tumor size were associated with worse oncology stage, but this was not evidenced in adenocarcinoma.
Conclusion: Weight loss (kg), BMI variation (kg/m²) and percentage of weight loss are factors that predict worse stage at diagnosis in the squamous cell carcinoma. In adenocarcinoma, these findings were not statistically significant.

Entities:  

Mesh:

Year:  2016        PMID: 27759773      PMCID: PMC5074661          DOI: 10.1590/0102-6720201600030003

Source DB:  PubMed          Journal:  Arq Bras Cir Dig        ISSN: 0102-6720


INTRODUCTION

Despite recent advances in diagnosis and treatment, esophageal cancer still has high mortality. Mean survival for squamous cell carcinoma (SCC) is 13.95±SD 11.2 months and for esophageal adenocarcinoma (EA) is 13.22±SD 10.23 months , , . Prognostic factors associated with patient and with disease itself are multiple and poorly explored. Knowing these parameters can allow a better stratification of high-risk groups , . This study aims to assess demographic, clinical and pathological factors in esophageal cancer patients that impact in overall survival and prognostic.

METHODS

This study retrospectively reviewed esophageal cancer patients that were admitted at an oncology referral center between 2009 and 2012. The analyzed variables were age, sex, performance status, past oncologic history, family oncologic history, tumor size, weight loss and body mass index, tumor location, grade of cellular differentiation, oncologic stage, lymphatic dissection, and curative intent resection. The studied population was composed of 565 individuals (n=565), of which 444 were SCC and 105 EA. The remaining was composed of other less frequent tumors, such as neuroendocrine tumors. Demographic, pathological and clinical characteristics were analyzed and compared to clinical stage and overall survival at 60 months. Average follow-up was 19.8 months.

Statistical Analysis

Regarding statistical analysis, to compare group means, ANOVA test was used; to analyze Kaplan-Meier curves, Log-Rank and Wilcoxon tests were used. Influence of prognostic variables was assessed by Cox regression. Significance level admitted was 0.05.

RESULTS

No difference was noted between SCC and EA overall survival curves. After five years, SCC presented 22.81% survival rate against 20.19% for EA (Figure 1).
FIGURE 1

Kaplan-Meier curves of survival, comparing esophageal adenocarcinoma (EA) and squamous cell carcinoma (SCC). There is no statistical difference between the curves (Log-Rank p-value=0.473; Wilcoxon p-value 0.098)

Of all of the EA patients, 30.4% were eligible for curative intent surgery. This proportion was 20% in SCC patients (p-value for Log-Rank 0.114; for Wilcoxon 0.042). After five years, survival for EA was 58% and for SCC 56.6%. By univariate analysis, curative intention resection was clearly associated to a better survival rate (p-value < 0.001). Figure 2 and 3 present overall survival curves according to oncologic stages at diagnosis.
FIGURE 2

Esophageal adenocarcinoma: overall survival curves according to oncologic stages at diagnosis

Longitudinal neoplasm extension at diagnosis was compared to clinical oncologic stage. By Chi-square analysis, it was noted that neoplasm size relate to poor prognosis in SCC (p-value 0.00), but not in EA (p-value 0.173). By univariate Cox regression, only in SCC tumor size was related to survival (p-value 0.001). Degree of cellular differentiation was related to poor clinical stage in SCC (Chi-Sq=27.831; DF=6; p-value=0.00), but not in EA (Chi-Sq=7.943; DF=6; p-value=0.242). Weight loss (kg), BMI variation (kg/m²) and percentage of weight loss from initial symptoms to the diagnosis of esophageal carcinoma are factors that predict worse oncologic stage at diagnosis in the SCC. In EA, this finding was not statistically significant (Figure 5). By logistic regression, BMI lower than 20 kg∕m² was a predictor of poor survival rate. Considering only patients submitted to curative intent surgery, more than 23 node resection could not reach a statistically significant improvement in survival rate by univariate analysis (p=0.678 in EA and p=0.493 in SCC). By univariate and multivariate analysis (Tables 1 and 2), variables associated to poor survival rate in EA was weight loss, performance status at the moment of diagnosis and distal location tumors; for SCC, male sex, weight loss, performance status, past history of other malignances and delay in initiating treatment. For both carcinoma types, curative intention resection was more often associated to better prognosis.
TABLE 1

Univariate and multivariate prognostic factors analysis for esophageal adenocarcinoma

†=not possible to estimate; ‡: =at the time of diagnosis; §= time between initial symptoms to diagnosis; ¶=time between diagnosis and initial oncologic treatment; HR=hazard ratio; ECOG=Eastern Cooperative Oncology Group performance status; KPS=Karnofsky performance status

†=not possible to estimate; ‡: =at the time of diagnosis; §= time between initial symptoms to diagnosis; ¶=time between diagnosis and initial oncologic treatment; HR=hazard ratio; ECOG=Eastern Cooperative Oncology Group performance status; KPS=Karnofsky performance status ‡=at the time of diagnosis; §=time between initial symptoms to diagnosis; ¶=time between diagnosis and initial oncologic treatment; HR=hazard ratio; ECOG=Eastern Cooperative Oncology Group performance status; KPS= Karnofsky performance status

DISCUSSION

Several factors have been related to prognosis in esophageal carcinoma , , . The present study analyzed prognostic factors associated to patients (age, gender, performance status, past oncologic history, family oncologic history, weight loss and body mass index); factors associated to neoplasm (tumor size, tumor location, grade of cellular differentiation, stage of cancer); and factors associated to treatment (quality of lymphadenopathy, curative intent resection).

Factors associated to patients

Age had association to bad prognosis only in SCC patients. Eloubeidi et al. also attributed elderly to poor survival rate . Previous paper demonstrated also that family history of esophageal cancer can predict bad prognosis . This finding is not in agreement with the present study.

Factors associated to neoplasm

High tumor size and high oncologic stage was associated with high mortality in SCC. This is in accordance with previous papers , . This study evinces SCC with poor cellular differentiation leads to a poor oncologic stage at the moment of diagnosis. Tachibana et al. also demonstrated an association of differentiation grade and prognosis.

Factors associated to surgery

Although it could not be demonstrated the relationship between survival and number of dissected lymphnodes, other studies showed a great importance of this variable. The number of positive lymph nodes (more vs. less than 5 dissected nodes) is related to an increasing risk of mortality (hazard ratio [HR], 1.29; 95% confidence interval [95%CI], 1.06 -1.56) according to Eloubeidi et al. Rizk et al. showed that patients with more than four involved lymph nodes have survival similar to that of patients with M1 disease. Consequently, the number of lymph nodes removed would be an independent factor for prognosis. For Peyre et al , a minimum of 23 regional lymph nodes should be removed. In this study, survival improvement after curative intent surgery must be carefully analyzed, once selection for surgery (only not advanced stages) may be a bias.

CONCLUSION

Esophageal carcinoma is a poor prognosis disease. In our study, after five years of follow-up, overall survival is next to 20%. Weight loss (kg), BMI variation (kg/m²) and percentage of weight loss are factors that predict worse stage at diagnosis in the squamous cell carcinoma. In adenocarcinoma, these findings were not statistically significant.
TABLE 2

Univariate and multivariate prognostic factors analysis for squamous cell carcinoma

‡=at the time of diagnosis; §=time between initial symptoms to diagnosis; ¶=time between diagnosis and initial oncologic treatment; HR=hazard ratio; ECOG=Eastern Cooperative Oncology Group performance status; KPS= Karnofsky performance status

  13 in total

1.  7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction.

Authors:  Thomas W Rice; Eugene H Blackstone; Valerie W Rusch
Journal:  Ann Surg Oncol       Date:  2010-07       Impact factor: 5.344

2.  The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system.

Authors:  Nabil Rizk; Ennapadam Venkatraman; Bernard Park; Raja Flores; Manjit S Bains; Valerie Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2006-12       Impact factor: 5.209

3.  Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status.

Authors:  Mohamad A Eloubeidi; Renee Desmond; Miguel R Arguedas; Carolyn E Reed; C Mel Wilcox
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

4.  Quality of life of esophagectomized patients: adenocarcinoma versus squamous cell carcinoma.

Authors:  Maricilda Regina Pereira; Luiz Roberto Lopes; Nelson Adami Andreollo
Journal:  Rev Col Bras Cir       Date:  2013 Jan-Feb

5.  Esophageal cancer patients surviving 6 years after esophagectomy.

Authors:  Mitsuo Tachibana; Dipok Kumar Dhar; Shoichi Kinugasa; Hiroshi Yoshimura; Toshiyuki Fujii; Muneaki Shibakita; Satoshi Ohno; Shuhei Ueda; Hitoshi Kohno; Naofumi Nagasue
Journal:  Langenbecks Arch Surg       Date:  2002-04-30       Impact factor: 3.445

6.  Total esophagogastrectomy in the neoplasms of the esophagus and esofagogastric junction: when must be indicated?

Authors:  Nelson Adami Andreollo; João de Souza Coelho Neto; Guilherme Delfino Calomeni; Luiz Roberto Lopes; Valdir Tercioti Junior
Journal:  Rev Col Bras Cir       Date:  2015 Nov-Dec

7.  Metastatic lymph node ratio, 6th or 7th AJCC edition: witch is the best lymph node classification for esophageal cancer? Prognosis factor analysis in 487 patients.

Authors:  Roberto V Coral; André V Bigolin; Roberto P Coral; Antonio Hartmann; Carolina Dranka; Adriana V Roehe
Journal:  Arq Bras Cir Dig       Date:  2015 Apr-Jun

8.  Impact of minimally invasive surgery in the treatment of esophageal cancer.

Authors:  M Italo Braghetto; H Gonzalo Cardemil; B Carlos Mandiola; L Gonzalo Masia; S Francesca Gattini
Journal:  Arq Bras Cir Dig       Date:  2014 Nov-Dec

9.  Evaluation of urgent esophagectomy in esophageal perforation.

Authors:  José Luis Braga de Aquino; José Gonzaga Teixeira de Camargo; Gustavo Nardini Cecchino; Douglas Alexandre Rizzanti Pereira; Caroline Agnelli Bento; Vânia Aparecida Leandro-Merhi
Journal:  Arq Bras Cir Dig       Date:  2014 Nov-Dec

10.  Standardized clinical pathways for esophagectomy are not a reality in Brazil, even with a high prevalence of esophageal cancer and achalasia.

Authors:  Marina Zamuner; Fernando A M Herbella; José L B Aquino
Journal:  Arq Bras Cir Dig       Date:  2015 Jul-Sep
View more
  19 in total

1.  Expression profile, clinical significance and biological functions of IGF2BP2 in esophageal squamous cell carcinoma.

Authors:  Fenying Lu; Weichang Chen; Tingwang Jiang; Cuie Cheng; Bin Wang; Zhiping Lu; Guojin Huang; Jiaming Qiu; Wei Wei; Ming Yang; Xia Huang
Journal:  Exp Ther Med       Date:  2022-02-01       Impact factor: 2.447

2.  Preoperative transferrin level is a novel indicator of short- and long-term outcomes after esophageal cancer surgery.

Authors:  Taishi Yamane; Hiroshi Sawayama; Naoya Yoshida; Takeshi Morinaga; Takahiko Akiyama; Kojiro Eto; Kazuto Harada; Katsuhiro Ogawa; Masaaki Iwatsuki; Shiro Iwagami; Yoshifumi Baba; Yuji Miyamoto; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2021-09-29       Impact factor: 3.402

3.  Investigating Esophageal Stent-Placement Outcomes in Patients with Inoperable Non-Cervical Esophageal Cancer.

Authors:  Mojgan Forootan; Morteza Tabatabaeefar; Nariman Mosaffa; Hormat Rahimzadeh Ashkalak; Mohammad Darvishi
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

4.  Survival predictors associated with signet ring cell carcinoma of the esophagus (SRCCE): A population-based retrospective cohort study.

Authors:  Zihao Wan; Zhihao Huang; Liaobin Chen
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

5.  Chemoradiotherapy With or Without Surgery for Esophageal Squamous Cancer According to Hospital Volume.

Authors:  Mateus Bringel Oliveira Duarte; Eduardo Baldon Pereira; Luiz Roberto Lopes; Nelson Adami Andreollo; José Barreto Campello Carvalheira
Journal:  JCO Glob Oncol       Date:  2020-06

6.  Distinct Local and Systemic Molecular Signatures in the Esophageal and Gastric Cancers: Possible Therapy Targets and Biomarkers for Gastric Cancer.

Authors:  Iwona Bednarz-Misa; Paulina Fortuna; Dorota Diakowska; Natalia Jamrozik; Małgorzata Krzystek-Korpacka
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

7.  PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.

Authors:  Nelson Adami Andreollo; Giovanni de Carvalho Beraldo; Iuri Pedreira Filardi Alves; Valdir Tercioti-Junior; José Antonio Possato Ferrer; João de Souza Coelho-Neto; Luiz Roberto Lopes
Journal:  Arq Bras Cir Dig       Date:  2018-12-06

8.  Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.

Authors:  Carolina Ribeiro Victor; Fernanda Kaori Fujiki; Flavio Roberto Takeda; Paulo Marcelo Gehm Hoff; Tiago Biachi de Castria
Journal:  J Glob Oncol       Date:  2019-07

9.  A Spatial Survival Model in Presence of Competing Risks for Iranian Gastrointestinal Cancer Patients

Authors:  Saeed Hesam; Mahmood Mahmoudi; Abbas Rahimi Foroushani; Mehdi Yaseri; Mohammad Ali Mansournia
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26

10.  Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials.

Authors:  Tarun Kumar; Esha Pai; Rajesh Singh; Neville J Francis; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2020-03-21       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.